Evotec SE reports results for the first nine months 2023 and provides ...
Evotec SE today announced the financial results and corporate updates for the first nine months 2023.
View ArticleEvotec presents precision medicine platforms for accelerated pipeline...
Evotec SE today presents at its Capital Markets Day how the Company is driving more efficient pipeline building towards assets, that are progressing with higher probabilities of success.
View ArticleEvotec SE today announced the expansion of its $ 20 m beLAB1407 BRIDGE...
Evotec SE today announced the expansion of its $20 million beLAB1407 BRIDGE partnership with Bristol Myers Squibb to include the Universities of Bristol and Glasgow as well as Queen Mary University of...
View ArticleEvotec-partner Jingxin receives approval for EVT201 in China
Evotec SE announced today that Zhejiang Jingxin Pharmaceutical Co., Ltd (“Jingxin”) has received the approval from the Chinese National Medical Products Administration (“NMPA”) for the novel insomnia...
View ArticleEvotec enters partnership with Charité to expand molecular patient ...
Evotec SE announced today that the Company has entered a partnership with Charité – Universitätsmedizin Berlin (“Charité”), one of the leading and largest university hospitals in Europe, to generate a...
View ArticleEvotec receives US$ 2.5 m grant to leverage human iPSC-derived ...
Evotec SE announced today that the Company has received a US$ 2.5 m grant from the Bill & Melinda Gates Foundation (“the foundation”) for its teratogenicity platform, and joins the foundation’s...
View ArticleEvotec announces CEO transition
Evotec SE today announced that after close to 15 years of successful service, CEO Dr Werner Lanthaler has informed the company, that he will not continue to serve until the end of his current term...
View ArticleAd hoc: Evotec announces CEO transition
Evotec SE announces that CEO Dr Werner Lanthaler has informed the company, that he has decided to step down as CEO and will not continue to serve until the end of his current term, for personal...
View ArticleEvotec and Owkin enter an A.I.-powered strategic partnership to...
Evotec SE and Owkin, a French-American techbio company today announced an A.I.-powered integrated multi-target collaboration in oncology, immunology and inflammation (“I&I”).
View ArticleEvotec announces progress in strategic neuroscience partnership with ...
Evotec SE today announced progress within the Company’s strategic partnership with Bristol Myers Squibb, further bolstering the joint pipeline of advanced neuroscience programmes. Evotec receives a...
View ArticleEvotec and Crohn´s & Colitis Foundation enter agreement to advance drug ...
Evotec SE today announced that the Company has joined forces with the Crohn’s & Colitis Foundation (“the Foundation”), the leading non-profit organisation focused on both research and patient...
View ArticleEvotec SE: Invitation to Conference Call
Evotec SE is going to hold a conference call to provide a statement as well as a business update on Monday, 22 January 2024.
View ArticleJust – Evotec Biologics expands development and manufacturing agreement....
Evotec SE today announced that its Seattle-based subsidiary Just – Evotec Biologics, Inc. has expanded its relationship with Advanced BioScience Laboratories, Inc. (“ABL”), a global contract...
View ArticleDeveloping novel strategies against tuberculosis and malaria
Tuberculosis and malaria are among the deadliest infectious diseases worldwide and are increasingly spreading, not least due to climate change. In both cases, antimicrobial resistance renders...
View ArticleEvotec and Claris Ventures streamline access to accelerate programmes ...
Evotec SE and biotech venture capital firm Claris Ventures (“Claris”) today announced an acceleration framework to streamline programmes from Claris’s portfolio companies into the clinic through...
View ArticleTubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical ...
Tubulis today announced the successful completion of an upsized and oversubscribed €128 million ($138.8 million) Series B2 financing. The round was co-led by EQT Life Sciences and Nextech Invest Ltd,...
View ArticleBreakpoint Therapeutics Announces Development Candidate Nomination and ...
Breakpoint Therapeutics GmbH (“Breakpoint”), a company dedicated to the discovery and development of drugs targeting the DNA Damage Response (DDR), announced today that it has nominated its first...
View ArticleEvotec welcomes Aurélie Dalbiez as Chief People Officer
Evotec SE today announced the appointment of Aurélie Dalbiez as the Company’s new Chief People Officer (“CPO”), effective 15 June 2024. Aurélie will be joining Evotec’s Management Board, bringing with...
View ArticleEvotec SE: To announce results for fiscal year 2023 on 24 April 2024
Evotec SE will announce its financial results for 2023 on Wednesday, 24 April 2024.
View ArticleEvotec and Variant Bio enter strategic partnership to discover and...
Evotec SE and Variant Bio, Inc. today announced a collaboration agreement to identify a best-in-class treatment for diseases caused by fibrosis.
View Article